Advanced Enzyme Tech financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹190cr+2.1% on Q1 FY26
Net profit
₹38.6cr−4.6% on Q1 FY26
EBITDA margin
26.9%−3.5 pts on Q1 FY26
EPS
₹3.31−7.3% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue190186+2.1%
EBITDA51.056.4−9.7%
EBITDA margin26.9%30.4%−3.5 pts
Profit before tax53.554.9−2.5%
Net profit38.640.4−4.6%
EPS₹3.31₹3.57−7.3%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹190 crNet profit₹38.6 crNet margin20.3%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
2,907————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
693693574517456
51.251.247.847.049.1
20.520.521.525.113.2
2,286————
750746637624541
—+17.1%+2.1%+15.4%—
224229194204156
29.8%30.7%30.5%32.8%28.9%
183189158169121
172174134137104
22.9%23.3%21.0%22.0%19.2%
₹14.82₹15.07₹11.71₹11.91₹9.44
—+28.7%−1.6%+26.2%—
—157142141140
—−52.4−34.8−42.4−38.2
10410410899.0102
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ADVENZYMES₹259.75

Advanced Enzyme Tech Ltd.

· Pharma & Health
₹ CrorePeersAARTIPHARMAARTIDRUGSAGARWALEYEAKUMSALIVUSAPLLTDCORONAHCGMcap ₹2,907 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————2,907.3
- Cash, Equiv & ST Investments456.0516.6574.5692.6692.6
+ Minority Interest49.147.047.851.251.2
+ Total Debt13.225.121.520.520.5
Enterprise Value————2,286.4
Revenue540.6623.9636.9745.8749.6
Growth %, YoY—+15.4+2.1+17.1—
EBITDA156.4204.5194.4229.1223.6
Margin %28.9432.7730.5330.7229.83
EBIT121.4169.2157.9189.0183.2
Net Income103.9137.0134.0173.6171.8
Margin %19.2121.9521.0323.2822.91
EPS, Adj (current shares)9.4411.9111.7115.0714.82
Growth %, YoY—+26.2-1.6+28.7—
Cash from Operations140.4141.4142.5156.8—
Capital Expenditures-38.2-42.4-34.8-52.4—
Free Cash Flow102.299.0107.7104.4104.4
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Advanced Enzyme Tech financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Advanced Enzyme Tech (NSE: ADVENZYMES) had a market capitalisation of ₹2,958 crore at the 29 October 2026 close (₹264.15 a share), a PE ratio of 17.8 on the last four quarters' profit and a price-to-book ratio of 1.81. In FY26 its consolidated net profit attributable to shareholders was ₹169 crore on revenue of ₹746 crore; in Q1 FY27 (April–June 2026) it was ₹37.1 crore, down 7.1% year on year. Its debt-to-equity ratio was 0.01 on 31 March 2026. Promoters held 43.56% of the shares on 30 September 2026.

Share price used
₹264.15 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Advanced Enzyme Tech at a glance · consolidated

Market cap
₹2,958 Crat ₹264.15 · 29 Oct close
PE ratio (last 4 quarters)
17.817.5 on FY26 profit
Price to book (PB)
1.81book value ₹145.74 a share
ROE (FY26)
11.1%+1.5 pts vs FY25ROCE 11.6%
Debt to equity
0.01net cash ₹679 Cr
Promoter holding
43.56%+0.3 pts vs 30 Jun 202630 September 2026
Dividend yield
0.51%₹1.35 a share in 12 months
Net worth
₹1,632 Cr+14.9% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹104 Cr−3.1% vs FY25

Questions

What is the Advanced Enzyme Tech PE ratio today?

Advanced Enzyme Tech's PE ratio is 17.8 at the 29 October 2026 close (₹264.15 a share): a market capitalisation of ₹2,958 crore divided by consolidated net profit attributable to shareholders of ₹166 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹169 crore) it is 17.5.

What is the Advanced Enzyme Tech PB ratio (price to book value)?

Advanced Enzyme Tech's price-to-book (PB) ratio is 1.81 at the 29 October 2026 close: a market capitalisation of ₹2,958 crore divided by shareholders' equity (book value) of ₹1,632 crore on 31 March 2026. That is a book value of ₹145.74 per share against a share price of ₹264.15.

What is the Advanced Enzyme Tech ROE and ROCE?

In FY26, Advanced Enzyme Tech's return on equity (ROE) was 11.1% and its return on capital employed (ROCE) was 11.6%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 9.6% and ROCE 10.7%.

What is the Advanced Enzyme Tech market cap?

Advanced Enzyme Tech's market capitalisation was ₹2,958 crore at the 29 October 2026 close: 11.2 crore shares at ₹264.15 each.

Is Advanced Enzyme Tech debt free?

No. Advanced Enzyme Tech had borrowings of ₹20.5 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.01. Its cash and current investments were ₹700 crore, so it held net cash of ₹679 crore.

What is the Advanced Enzyme Tech dividend in 2026 and its record date?

In 2026, Advanced Enzyme Tech has declared one dividend: ₹1.35 with record date 24 July 2026.

What is the Advanced Enzyme Tech debt to equity ratio?

Advanced Enzyme Tech's debt-to-equity ratio was 0.01 on 31 March 2026: borrowings of ₹20.5 crore against total equity of ₹1,683 crore. A year earlier, on 31 March 2025, it was 0.01.

What is the Advanced Enzyme Tech net worth?

Advanced Enzyme Tech's net worth — shareholders' equity in its consolidated balance sheet — was ₹1,632 crore on 31 March 2026, up 14.9% from ₹1,421 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹2,958 crore at the 29 October 2026 close.

What is the Advanced Enzyme Tech book value per share?

Advanced Enzyme Tech's book value per share was ₹145.74 on 31 March 2026: shareholders' equity of ₹1,632 crore divided by the 11.2 crore shares in issue, up 14.8% from ₹127.00 a year earlier. The share price at the 29 October 2026 close was ₹264.15.

What is the Advanced Enzyme Tech EPS?

Advanced Enzyme Tech's basic earnings per share (EPS) were ₹15.08 in FY26, against ₹11.72 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹14.82.

What is the Advanced Enzyme Tech dividend yield?

Advanced Enzyme Tech's dividend yield is 0.51% at the 29 October 2026 close: dividends of ₹1.35 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹264.15. They were ₹1.35 on 24 July 2026.

When are the Advanced Enzyme Tech next results?

Advanced Enzyme Tech will announce its Q2 FY27 results (July–September 2026) on Saturday, 31 October 2026, the date of the board meeting it has notified to the exchanges.

What is the Advanced Enzyme Tech promoter holding?

Promoters held 43.56% of Advanced Enzyme Tech on 30 September 2026, up 0.32 percentage points from 43.24% the previous quarter and up 0.49 percentage points from 43.07% a year earlier, according to the shareholding pattern filed with NSE.

What is the Advanced Enzyme Tech free cash flow?

In FY26, Advanced Enzyme Tech generated ₹157 crore of cash from operations and spent ₹52.4 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹104 crore. In FY25 it was ₹108 crore.

What are the Advanced Enzyme Tech latest quarterly results?

Advanced Enzyme Tech's latest results are for Q1 FY27 (April–June 2026), filed on 8 August 2026: consolidated net profit attributable to shareholders ₹37.1 crore, down 7.1% from ₹39.9 crore in Q1 FY26; revenue from operations ₹190 crore, up 2.1% year on year.

What is the Advanced Enzyme Tech shareholding pattern?

On 30 September 2026, Advanced Enzyme Tech's shares were held by promoters 43.56%, foreign portfolio investors (FII/FPI) 26.65%, domestic institutions (DII) 1.89% (including mutual funds at 1.18%) and retail and other non-institutional investors 27.90%. Over the year, FII holding was up 1.24 percentage points from 25.41% and DII holding was down 4.52 percentage points from 6.41%.

How does Advanced Enzyme Tech compare with its peers?

On FY26 consolidated figures, against Aarti Pharmalabs, Aarti Drugs and Dr. Agarwal's Health Care: Advanced Enzyme Tech's operating margin of 25.3% is the highest of the four (Aarti Pharmalabs 14.6%, Aarti Drugs 9.4%, Dr. Agarwal's Health Care 14.1%; peer average 12.7%); its return on equity of 11.1% is the second highest of the four (Aarti Pharmalabs 8.4%, Aarti Drugs 13.4%, Dr. Agarwal's Health Care 6.8%; peer average 9.5%).

How does the Advanced Enzyme Tech PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Advanced Enzyme Tech's PE ratio is 17.5, the lowest of the four: Aarti Pharmalabs 48.7, Aarti Drugs 21.0 and Dr. Agarwal's Health Care 116.3, a peer average of 62.0. Each is the company's market capitalisation at that price divided by its FY26 net profit.

What is the Advanced Enzyme Tech revenue and profit in FY26?

In FY26 (April 2025–March 2026), Advanced Enzyme Tech's consolidated net profit attributable to shareholders was ₹169 crore, up 28.7% from ₹131 crore in FY25, on revenue from operations of ₹746 crore (up 17.1%). Over three years, from FY23, net profit was up 59.7%.

Advanced Enzyme Tech vs Aarti Pharmalabs: how do they compare?

In FY26, Advanced Enzyme Tech earned net profit attributable to shareholders of ₹169 crore on revenue of ₹746 crore, against ₹173 crore on ₹1,819 crore for Aarti Pharmalabs. Advanced Enzyme Tech's operating margin was 25.3% (Aarti Pharmalabs 14.6%) and its return on equity 11.1% (Aarti Pharmalabs 8.4%). At the 29 October 2026 close, Advanced Enzyme Tech's market capitalisation was ₹2,958 crore against ₹8,412 crore for Aarti Pharmalabs, and its PE ratio on FY26 profit 17.5 against 48.7.

Where do these Advanced Enzyme Tech figures come from?

From Advanced Enzyme Tech's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.